HomeCompareAAVMY vs JNJ

AAVMY vs JNJ: Dividend Comparison 2026

AAVMY yields 4.65% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AAVMY wins by $4096.92M in total portfolio value
10 years
AAVMY
AAVMY
● Live price
4.65%
Share price
$31.87
Annual div
$1.48
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4096.95M
Annual income
$3,934,405,054.61
Full AAVMY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — AAVMY vs JNJ

📍 AAVMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAAVMYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AAVMY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AAVMY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AAVMY
Annual income on $10K today (after 15% tax)
$395.25/yr
After 10yr DRIP, annual income (after tax)
$3,344,244,296.42/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, AAVMY beats the other by $3,344,240,310.43/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AAVMY + JNJ for your $10,000?

AAVMY: 50%JNJ: 50%
100% JNJ50/50100% AAVMY
Portfolio after 10yr
$2048.49M
Annual income
$1,967,204,872.01/yr
Blended yield
96.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AAVMY
Analyst Ratings
3
Buy
3
Hold
1
Sell
Consensus: Buy
Altman Z
-0.6
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AAVMY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAAVMYJNJ
Forward yield4.65%2.13%
Annual dividend / share$1.48$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$4096.95M$30.3K
Annual income after 10y$3,934,405,054.61$4,689.40
Total dividends collected$4085.48M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: AAVMY vs JNJ ($10,000, DRIP)

YearAAVMY PortfolioAAVMY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,630$929.99$10,592$272.30+$1.0KAAVMY
2$14,466$2,021.64$11,289$357.73+$3.2KAAVMY
3$20,178$4,700.15$12,123$472.89+$8.1KAAVMY
4$33,846$12,254.78$13,141$629.86+$20.7KAAVMY
5$74,636$38,420.91$14,408$846.81+$60.2KAAVMY
6$238,225$158,364.28$16,021$1,151.60+$222.2KAAVMY
7$1,199,706$944,805.85$18,122$1,588.22+$1.18MAAVMY
8$10,177,273$8,893,587.76$20,930$2,228.20+$10.16MAAVMY
9$151,909,367$141,019,684.70$24,792$3,191.91+$151.88MAAVMY
10$4,096,948,078$3,934,405,054.61$30,274$4,689.40+$4096.92MAAVMY

AAVMY vs JNJ: Complete Analysis 2026

AAVMYStock

ABN AMRO Bank N.V. provides various banking products and services to retail, private, and business clients in the Netherlands and internationally. It operates through three segments: Personal & Business Banking, Wealth Management, and Corporate Banking. The company provides savings and deposits products; labelled residential mortgage products under the Florius brands; and consumer loans under the Alpha Credit Nederland, Credivance, Defam, Moneyou, and ABN AMRO brands. It also issues, promotes, manages, and processes credit cards; provides revolving credit card facilities and pension schemes, as well as consumer credit and mortgages; and life and non-life insurance products. In addition, it offers asset-based solutions, including working capital solutions, equipment leases and loans, and vendor lease services; private banking and wealth-management-related services; and derivatives and equity clearing services. ABN AMRO Bank N.V. was incorporated in 2009 and is headquartered in Amsterdam, the Netherlands.

Full AAVMY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AAVMY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AAVMY vs SCHDAAVMY vs JEPIAAVMY vs OAAVMY vs KOAAVMY vs MAINAAVMY vs ABBVAAVMY vs MRKAAVMY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.